#
call menu

APTT Test

According to the Russian Federation (RF) as of 2021: Reagent kit for the determination of Activated Partial Thromboplastin Time (APTT Test) according to TU 9398-017-05595541-2009.

According to the Russian Federation (RF) as of 2021: Reagent kit for the determination of Activated Partial Thromboplastin Time in blood plasma using the clotting method (APTT Test) according to TU 21.20.23-069-05595541-2020.

Activated Partial Thromboplastin Time (APTT) is one of the most common and sensitive tests for detecting a wide range of coagulation disorders. APTT varies depending on various quantities of fibrinogen, prothrombin activity, factors V, VIII, IX, X, XI, XII, contact factors, and the presence of specific inhibitors of coagulation factors VIII and IX. APTT is widely used as a method for monitoring the effectiveness of parenteral administration of heparin, where clotting time increases proportionally to the level of heparin. In patients taking oral anticoagulants, levels of circulating factors II, VII, IX, and X are reduced, leading to an increase in APTT. In the presence of nonspecific inhibitors, such as lupus anticoagulant, APTT may be prolonged.

The reagent kit for the determination of Activated Partial Thromboplastin Time (APTT Test) is designed to work on all types of semi-automatic and automatic coagulometers.

Method principle: To the examined blood plasma, APTT reagent is sequentially added, which is a mixture of soy phospholipids, ellagic acid, HEPES buffer, stabilizer, and the preservative ProClin 300. During the APTT measurement, the time from the addition of calcium ions to the formation of a clot is recorded.

  • #

Kit Composition:

Catalog number PG-7/1 by the manufacturer:

  • APTT Reagent, lyophilized, volume after reconstitution 4.0 ml in a vial – 7 vials.
  • Calcium chloride 0.025 M solution, 10.0 ml in a vial – 3 vials.

Catalog number PG-7/3 by the manufacturer:

  • APTT Reagent, liquid, 5.0 ml in a vial – 5 vials.
  • Calcium chloride 0.025 M solution, 5.0 ml in a vial – 5 vials.

In the PG-7/1 variant, all components of the kit are packaged in glass vials, sealed with rubber stoppers, and crimped with aluminum caps.

In the PG-7/3 variants, all components of the kit are packaged in glass vials, sealed with rubber stoppers, and equipped with polymer screw caps.

The kit is designed for 560 determinations (PG-7/1 variant) or 500 determinations (PG-7/3 variant) with a consumption of 50 µl of each reagent per determination.

Normal and pathological values of the APTT test should be monitored using Control Plasma (pool of healthy donors) (Plasma N), code KM-1.